Lisocabtagene maraleucel - Celgene/Juno Therapeutics

Drug Profile

Lisocabtagene maraleucel - Celgene/Juno Therapeutics

Alternative Names: anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; EGFRt-4-1BB-modified-CAR-CD8+-and-CD4+-T-lymphocytes-Juno-Therapeutics; Gene modified autologous T cells; JCAR 017; Liso-cel

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juno Therapeutics
  • Developer Celgene Corporation; Juno Therapeutics; Seattle Children's Hospital
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 02 Jul 2018 Celgene plans the TRANSFORM phase III trial for Non-Hodgkin lymphoma (Late-stage disease) in July 2018 , (NCT03575351)
  • 25 Jun 2018 Celgene Corporation plans a phase Ib/II trial for B-cell acute lymphoblastic leukaemia and B-cell non-hodgkin lymphoma (Second-line therapy or greater) in Belgium (In infants, In toddlers, In childrens, In adolescents, In adults) (EudraCT2018-001246-34)
  • 05 Jun 2018 Phase-II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Spain (IV) (NCT03484702)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top